The New York-based company previously offered the opportunity for investors to exercise the Series W warrants at a discounted price of $2.00 per share. As of Feb. 8, Pavmed said 34,345 Series W warrants had been tendered for exercise and the company had raised $68,690 in gross cash proceeds.
Each of Pavmed’s outstanding Series W warrants can be exercised for one share of common stock at an exercise price of $5.00 per share until Jan. 29, 2022, while each Z warrant can be exercised for one share of common stock at $3.00 apiece until April 30, 2024.
Pavmed noted that if all W warrants are exchanged as part of its latest offer, the company’s common stock will be cut by 5,283,992 shares.
Pavmed also raised $3.9 million in public offering at the end of last month, saying that it planned to use the funds for working capital and general corporate purposes.
The company sold 2.4 million shares of its common stock at $1.80 apiece in the offering, which also included a 45-day option for underwriters to buy an additional 362,292 shares of common stock to cover over-allotments.
On June 4-5, DeviceTalks is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring, bringing you the best and brightest minds in the industry.
Heidi Dohse: Sr. Program Manager, Healthcare, Google, Founder, Tour de Heart Foundation, Acessa Health Inc. Michael J. Pederson: Senior Vice President, Cardiac Arrhythmias and Heart Failure Division, Abbott Hon. Melvin Carter: Mayor, Saint Paul Tim Philips: Compliance Officer, FDA’s Office of Medical Device and Radiological Health Operations Dr. Myriam J. Curet, MD, FACS: Chief Medical Officer, Intuitive Surgical
Take a look at our incredible line up of speakers and join us now.
Use the code "KEYNOTE" to save 15% on the cost of registration.